MoonLake Immunotherapeutics (MLTX) Cash from Financing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 58.09% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $103.5 million (up 40.93% YoY), while the FY2025 annual figure was $146.0 million, up 184.53% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $30.6 million, down from $72.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $451.3 million in Q2 2023, with the low at $3791.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $29.5 million (2023), against an average of $68.9 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 99.99% in 2022, then soared 749462.31% in 2023.
• MoonLake Immunotherapeutics' Cash from Financing Activities stood at $3791.0 in 2022, then jumped by 749462.31% to $28.4 million in 2023, then slumped by 99.47% to $151000.0 in 2024, then surged by 47843.71% to $72.4 million in 2025, then tumbled by 57.67% to $30.6 million in 2026.
• Business Quant data shows MLTX's Cash from Financing Activities at $30.6 million in Q1 2026, $72.4 million in Q4 2025, and $480000.0 in Q3 2025.